Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:1933-1935

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jialal, I.
Right arrow Articles by Devaraj, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jialal, I.
Right arrow Articles by Devaraj, S.
Related Collections
Right arrow Lipid and lipoprotein metabolism

(Circulation. 2001;103:1933.)
© 2001 American Heart Association, Inc.


Brief Rapid Communication

Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels

Presented in part at the 73rd Scientific Sessions of the American Heart Association, New Orleans, La, November 12–15, 2000, and published in abstract form (Circulation. 2000;102[suppl II]:II-833).

I. Jialal, MD, PhD; D. Stein, MD; D. Balis, MD; S. M. Grundy, MD, PhD; B. Adams-Huet, MS; S. Devaraj, PhD

From the University of Texas Southwestern Medical Center at Dallas, Tex (I.J., D.B., S.M.G., B.A.H. S.D.), and Albert Einstein College of Medicine, Bronx, NY (D.S.).

Correspondence to I. Jialal, MD, PhD, Director, Division of Clinical Biochemistry and Human Metabolism, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9073. E-mail jialal.i{at}pathology.swmed.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—Prospective studies indicate that baseline levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. Limited studies have examined therapies that influence high-sensitive CRP (hs-CRP) levels, especially in hyperlipidemic patients. Thus, we tested the effects of 3 hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), simvastatin (20 mg/d), pravastatin (40 mg/d), and atorvastatin (10 mg/d), on levels of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipidemia (LDL cholesterol >130 mg/dL and triglycerides of 200 to 600 mg/dL).

Methods and Results—After 6 weeks of an American Heart Association Step 1 diet, fasting blood samples were drawn at baseline and after 6 weeks of therapy with each drug. hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). The reductions obtained with the 3 statins were similar. In addition, there was no significant effect on either plasma interleukin-6 or interleukin-6 soluble receptor levels. There was no relationship between reductions in hs-CRP and LDL cholesterol.

Conclusions—Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. These data support an anti-inflammatory effect of these drugs.


Key Words: statins • inflammation • C-reactive protein


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Recently, numerous trials with the hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) demonstrated a significant reduction in cardiovascular events.1 Although the majority of the effect could be ascribed to a beneficial effect on the lipid profile, the statins might have additional effects that could confer benefit. Inflammation seems to be a pivotal final step in acute coronary syndromes.2 3 The advent of a highly sensitive assay for C-reactive protein (CRP) has led to a greater understanding of the role of inflammation in coronary artery disease. CRP, a prototypic marker of inflammation, is driven by the proinflammatory cytokines interleukin (IL)-1, tumor necrosis factor-{alpha}, and IL-6.4 Numerous prospective epidemiological studies have clearly demonstrated an increased risk with increasing CRP levels.2 3 In addition, studies have demonstrated that CRP confers risk above that of an abnormal lipid profile.2 5 Thus, modalities targeting inflammation and reducing proinflammatory cytokines and CRP levels could be a potential additional strategy in the prevention of cardiovascular disease.

Regarding the statins, one study to date demonstrated that patients who have increased CRP levels (increased inflammation) have a greater benefit from pravastatin therapy6 and that median CRP levels were reduced 17.4% in the group that received pravastatin.7 Thus, it is important to determine whether this reduction in CRP is specific for pravastatin or if it also occurs with other commonly prescribed statins. The aim of the present study was to test if simvastatin and atorvastatin, at LDL-lowering doses similar to those of pravastatin (as determined by the CURVES study8 ), resulted in a significant reduction in high-sensitive CRP levels (hs-CRP).


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Patients
Patients were recruited from the Lipid Clinics at the University of Texas Southwestern Medical Center in Dallas. This protocol was approved by the Institutional Review Board, and all patients gave informed consent. Inclusion criteria for the subjects included an age of 18 to 70 years, a triglyceride level between 200 to 600 mg/dL, and an LDL cholesterol level >=130 mg/dL.

Exclusion criteria were as follows: use of lipid-lowering drugs or drugs known to affect lipid metabolism, use of antioxidant supplements, use of warfarin or heparin for the past 4 weeks, liver or renal dysfunction, diabetes, hypothyroidism, infection, cancer, and/or recent major surgery or illness.

Study Design
This was a randomized, double-blind, crossover study design. A total of 22 patients were enrolled. There was a 6-week lead-in dietary phase when the patients were instructed by the dietitian to follow an American Heart Association Step 1 diet for the study duration, followed by a 6-week drug therapy phase with a 3-week washout period between drugs. The statins used included simvastatin (20 mg/d), atorvastatin (10 mg/d), and pravastatin (40 mg/d).8

Three fasting blood samples were obtained at baseline (7 days apart), and 2 fasting blood samples were obtained during therapy with each drug (5.5 and 6 weeks). Levels of total cholesterol, total triglycerides, and LDL and HDL cholesterol were assayed by routine laboratory techniques, as reported previously.9 If plasma triglycerides were >400 mg/dL, LDL cholesterol was assessed by a direct method.9 Levels of CRP were measured by a highly sensitive nephelometric assay using a monoclonal antibody to CRP coated on polystyrene beads (Dade Behring). This assay is referenced to the World Health Organization standard and is sensitive in the range of 0.175 to 60 mg/L. Both interassay and intra-assay coefficients of variation were <5%. IL-6 and IL-6 soluble receptor levels in serum were measured using a highly sensitive immunoassay (R&D Systems). The intra-assay coefficient of variation was <4%.

Statistical Analyses
All statistical analyses were performed using SAS version 8.0. Because some variables were skewed (triglycerides, hs-CRP), nonparametric tests were used for these data. The number of replicates needed to achieve the validity coefficient of cholesterol (0.91) with CRP was 2.10 Treatment order for this crossover study was assessed with repeated measures ANOVA models using log transformations for skewed data.

The 3 statin drugs were compared with Friedman’s test and Wilcoxon signed rank test for pairwise comparisons: the means of the 3 baseline levels were compared with the 2 levels obtained on therapy. Weighted correlation coefficients were computed to assess associations between variables of interest.11 The level of significance was set at P<0.05 (2-sided).


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
The salient characteristics of the participants in this study are as follows: age, 47.2±9.7 years; male/female ratio, 10/12; and body mass index, 24.5±4.9 kg/m2. As is evident in the TableDown, there was a significant reduction in total and LDL cholesterol with all 3 statins; a significant reduction in plasma triglycerides was only seen with simvastatin and atorvastatin. None of the drugs had a significant effect on HDL cholesterol levels in these patients. As shown in the FigureDown, all 3 drugs resulted in a significant reduction in CRP levels. The percentage of patients showing a reduction of CRP with pravastatin, simvastatin, and atorvastatin was 72.7%, 81.8%, and 81.8%. A total of 54.6% of patients responded to all 3 statins. There were no significant differences in the median percent reduction in hs-CRP levels with pravastatin, simvastatin, and atorvastatin (20.3%, 22.8%, and 28.3%, respectively). Of the responders, >=40% of the reduction in CRP was seen in 31.3%, 38.8%, and 44.4% of patients receiving pravastatin, simvastatin, and atorvastatin, respectively.


View this table:
[in this window]
[in a new window]
 
Table 1. Effect of Statin Therapy on Lipid and Lipoprotein Levels



View larger version (13K):
[in this window]
[in a new window]
 
Figure 1. Effect of statin therapy on hs-CRP levels. Data are presented as 25th percentile, median, and 75th percentile. P indicates pravastatin; S, simvastatin; and A, atorvastatin. *P<0.025 compared with baseline.

Neither plasma IL-6 nor IL-6 soluble receptor levels were significantly reduced with any of the drugs (IL-6: baseline, 2.5±0.4 pg/mL; pravastatin, 2.6±0.5 pg/mL; simvastatin, 2.4±0.4 pg/mL; and atorvastatin, 2.8±0.5 pg/mL; P>0.4; IL-6 soluble receptor: baseline, 21.5±8.1 ng/mL; pravastatin, 21.0±7.5 ng/mL; simvastatin, 21.3±9.0 ng/mL; atorvastatin, 21.7±8.4 ng/mL; P>0.4). Although no significant correlation was found between changes in CRP levels and changes in LDL cholesterol (r=-0.1, P=0.7) or HDL cholesterol (r=0.04, P=0.9), the correlation with triglycerides was significant (r=0.59, P=0.005). Furthermore, while in the washout phase, LDL-cholesterol increased significantly (P<0.001) but, compared with the drug phase, there was no significant increase in CRP levels (P=0.21).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Whether CRP is a risk marker or risk factor will only be settled by future studies. To date, CRP has been localized to foam cells in atherosclerotic lesions, it colocalizes with activated complement fragments, and it induces adhesion molecule expression from the endothelium and tissue factor secretion from monocytes.3 12 13

Previously, Ridker et al6 showed that patients with hs-CRP levels in the upper quartile had a greater benefit (54% relative risk reduction) compared with those in the lowest quartile. Furthermore, they showed a significant reduction in hs-CRP with pravastatin therapy. In the present report, we confirm that pravastatin therapy results in a significant reduction in CRP levels. Furthermore, we show that simvastatin and atorvastatin also result in a significant reduction in CRP levels. There was no significant difference between the 3 statins regarding reductions in hs-CRP. Like the Cholesterol And Recurrent Events (CARE) study, we showed no significant correlations between total cholesterol, LDL cholesterol, or HDL cholesterol and hs-CRP levels. The increase in LDL-cholesterol but not CRP in the washout phase further underscores a divergence of statins on these 2 effects. However, we found a significant correlation between a reduction in triglycerides and hs-CRP levels. Because our sample size is small and pravastatin reduced CRP without having a significant effect on triglycerides, these findings need to be viewed with caution, and confirmation must await future studies.

This study explored a potential mechanism by which statins may result in a significant reduction in hs-CRP levels. IL-6 levels were measured, but statin drugs had no effect on IL-6 levels. Because there is a great circadian variation in IL-6 levels and our sample size is small, this finding needs to be viewed with caution. Plasma IL-6 may not be the best reflection of the IL-6 levels that bathe the liver. More meaningful data would have been obtained if IL-6 levels were measured after activation, because statin therapy resulted in a significant reduction in IL-6 in lipopolysaccharide-activated whole blood.14 Because IL-6 soluble receptor levels did not change, a decrease in IL-6 soluble receptor levels cannot explain the reduction in CRP.15 Another potential reason for a failure to see a reduction in IL-6 levels despite a reduction in CRP could be that statins are acting through IL-6–independent mechanisms.16

In conclusion, the present study makes the novel observation that pravastatin, atorvastatin, and simvastatin therapy result in a significant reduction in hs-CRP levels. Furthermore, all 3 statins reduced hs-CRP levels to a similar extent.

Recently, the present investigators showed that high-dose RRR-{alpha} tocopherol (1200 IU/d) resulted in a reduction in plasma hs-CRP levels and monocyte IL-6 levels in both controls and type 2 diabetic patients.17 In the Physician’s Health Study, patients with the highest CRP levels received the greatest benefit from aspirin therapy.18 Although studies with aspirin therapy are conflicting,19 20 the benefit of statins in reducing hs-CRP levels is supported by at least 2 studies to date. Further studies need to be directed toward elucidating the mechanism of reduction in CRP.


*    Acknowledgments
 
Supported by Merck, Warner-Lambert, and the National Institutes of Health (grants K24 AT00596 and MO1-RR-00633).

Received January 16, 2001; revision received February 15, 2001; accepted February 16, 2001.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Maron DJ, Fazio S, MacRae FL. Current perspectives on statins. Circulation. 2000;101:207–213.[Abstract/Free Full Text]

2. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am. 2000;84:149–161.[Medline] [Order article via Infotrieve]

3. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 1999;10:435–551.[Medline] [Order article via Infotrieve]

4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–351.[Free Full Text]

5. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;432:836–843.

6. Ridker PM, Rifai N, Pfeffer M, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839–844.[Abstract/Free Full Text]

7. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235.[Abstract/Free Full Text]

8. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–587.[Medline] [Order article via Infotrieve]

9. Maitra A, Hirany S, Jialal I. A comparison of two assays for the measurement of LDL cholesterol. Clin Chem. 1997;43:1040–1047.[Abstract/Free Full Text]

10. Sakkinen P, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. 1999;149:261–267.[Abstract/Free Full Text]

11. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations, part 2: correlation between subjects. BMJ. 1995;310:633.[Free Full Text]

12. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168.[Abstract/Free Full Text]

13. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2094–2099.[Abstract/Free Full Text]

14. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;353:983–984.[Medline] [Order article via Infotrieve]

15. Mackiewicz A, Schooltink H, Heinrich PC. Complex of soluble human Il-6-Receptor/Il-6 up-regulates expression of acute-phase proteins. J Immunol. 1992;149:2021–2027.[Abstract]

16. Weinhold B, Rüther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J. 1997;327:425–429.

17. Devaraj S, Jialal I. Alpha tocopherol supplementation decreases C-reactive protein and monocyte interleukin-6 levels in type 2 diabetic patients. Free Radic Biol Med,. 2000;29:790–792.[Medline] [Order article via Infotrieve]

18. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.[Abstract/Free Full Text]

19. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–798.[Abstract/Free Full Text]

20. Feng D-L, Tracy RP, Lipinska I, et al. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis. 2000;9:37–41.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Vasc MedHome page
F. J Khawaja and I. J Kullo
Novel markers of peripheral arterial disease
Vascular Medicine, November 1, 2009; 14(4): 381 - 392.
[Abstract] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
H. Hara, M. Nakamura, I. Yokouchi, K. Kimura, N. Nemoto, S. Ito, T. Ono, H. Itaya, M. Shiba, M. Wada, et al.
Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study
Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 357 - 365.
[Abstract] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
Y. Hu, G. Tong, W. Xu, J. Pan, K. Ryan, R. Yang, A. R. Shuldiner, D.-W. Gong, and D. Zhu
Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis
Diabetes and Vascular Disease Research, October 1, 2009; 6(4): 262 - 268.
[Abstract] [PDF]


Home page
HeartHome page
K. Swedberg
Fallacies in clinical cardiovascular trials
Heart, September 1, 2009; 95(17): 1464 - 1468.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Anselmi, G. Possati, and M. Gaudino
Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation?
Ann. Thorac. Surg., July 1, 2009; 88(1): 326 - 333.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Antonini-Canterin, E. Leiballi, R. Enache, B. A. Popescu, M. Rosca, E. Cervesato, R. Piazza, C. Ginghina, and G. L. Nicolosi
Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors Delay the Progression of Rheumatic Aortic Valve Stenosis: A Long-Term Echocardiographic Study
J. Am. Coll. Cardiol., May 19, 2009; 53(20): 1874 - 1879.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. S. Kelley, D. Siegel, D. M. Fedor, Y. Adkins, and B. E. Mackey
DHA Supplementation Decreases Serum C-Reactive Protein and Other Markers of Inflammation in Hypertriglyceridemic Men
J. Nutr., March 1, 2009; 139(3): 495 - 501.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. M Ridker
C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease
Clin. Chem., February 1, 2009; 55(2): 209 - 215.
[Full Text] [PDF]


Home page
LupusHome page
J. Sabio, M Zamora-Pasadas, J Jimenez-Jaimez, F Albadalejo, J Vargas-Hitos, M. Rodriguez del Aguila, C Hidalgo-Tenorio, M. Gonzalez-Gay, and J. Alonso
Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain
Lupus, September 1, 2008; 17(9): 849 - 859.
[Abstract] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
A. Z. LaCroix, S. L. Gray, A. Aragaki, B. B. Cochrane, A. B. Newman, C. L. Kooperberg, H. Black, J. D. Curb, P. Greenland, and N. F. Woods
Statin Use and Incident Frailty in Women Aged 65 Years or Older: Prospective Findings From the Women's Health Initiative Observational Study
J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2008; 63(4): 369 - 375.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. M. Mortensen, M. J. Pugh, L. A. Copeland, M. I. Restrepo, J. E. Cornell, A. Anzueto, and J. A. Pugh
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia
Eur. Respir. J., March 1, 2008; 31(3): 611 - 617.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
P. Dandona
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. Lertsburapa, C. M. White, J. Kluger, O. Faheem, J. Hammond, and C. I. Coleman
Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery.
J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 405 - 411.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
H. Shao, Y. Shen, H. Liu, G. Dong, J. Qiang, and H. Jing
Simvastatin Suppresses Lung Inflammatory Response in a Rat Cardiopulmonary Bypass Model
Ann. Thorac. Surg., December 1, 2007; 84(6): 2011 - 2018.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
J. S. Gortney and R. M. Sanders
Impact of C-reactive protein on treatment of patients with cardiovascular disease
Am. J. Health Syst. Pharm., October 1, 2007; 64(19): 2009 - 2016.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
K. Groschel, U. Ernemann, J. Larsen, M. Knauth, F. Schmidt, J. Artschwager, and A. Kastrup
Preprocedural C-Reactive Protein Levels Predict Stroke and Death in Patients Undergoing Carotid Stenting
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1743 - 1746.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
A. M. Andrei, R. Fraguas Jr., R. M.S. Telles, T. C.T.F. Alves, C. M.C. Strunz, A. Nussbacher, J. Rays, D. V. Iosifescu, and M. Wajngarten
Major Depressive Disorder and Inflammatory Markers in Elderly Patients With Heart Failure
Psychosomatics, August 1, 2007; 48(4): 319 - 324.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Momin, N. Melikian, S. B. Wheatcroft, D. Grieve, L. C. John, A. El Gamel, M. T. Marrinan, J. B. Desai, C. Driver, R. Sherwood, et al.
The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery
J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 335 - 341.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. Jialal, E. Miguelino, S. C. Griffen, and S. Devaraj
Concomitant Reduction of Low-Density Lipoprotein-Cholesterol and Biomarkers of Inflammation with Low-Dose Simvastatin Therapy in Patients with Type 1 Diabetes
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3136 - 3140.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. H. Olsen, T. W. Hansen, M. K. Christensen, F. Gustafsson, S. Rasmussen, K. Wachtell, H. Ibsen, C. Torp-Pedersen, and P. R. Hildebrandt
N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population
Eur. Heart J., June 1, 2007; 28(11): 1374 - 1381.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Ridker
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus
J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kinlay
Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis
J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
H. Kamishirado, T. Inoue, M. Sakuma, T. Tsuda, T. Hayashi, K. Takayanagi, and K. Node
Effects of Statins on Restenosis After Coronary Stent Implantation
Angiology, February 1, 2007; 58(1): 55 - 60.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. G. Koch, L. Li, D. R. Van Wagoner, A. I. Duncan, A. M. Gillinov, and E. H. Blackstone
Red Cell Transfusion is Associated With an Increased Risk for Postoperative Atrial Fibrillation
Ann. Thorac. Surg., November 1, 2006; 82(5): 1747 - 1756.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Devaraj, E. Chan, and I. Jialal
Direct Demonstration of an Antiinflammatory Effect of Simvastatin in Subjects with the Metabolic Syndrome
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4489 - 4496.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. Topakian, H.-P. Haring, and F. T. Aichner
Admission C-Reactive Protein as a Predictor for Stroke Outcome Among Candidates for Thrombolysis: Decision Adjourned
Stroke, October 1, 2006; 37(10): 2454 - 2454.
[Full Text] [PDF]


Home page
CirculationHome page
D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. D. Wiviott, M. A. Blazing, A. Shui, N. Rifai, R. M. Califf, and E. Braunwald
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
Circulation, July 25, 2006; 114(4): 281 - 288.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
M. Suzuki, M. Saito, T. Nagai, H. Saeki, and Y. Kazatani
Prevention of Positive Coronary Artery Remodeling with Statin Therapy in Patients with Coronary Artery Diseases
Angiology, May 1, 2006; 57(3): 259 - 265.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. Tsimikas, J. T. Willerson, and P. M. Ridker
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
S. E Kasim-Karakas, A. Tsodikov, U. Singh, and I. Jialal
Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake.
Am. J. Clinical Nutrition, April 1, 2006; 83(4): 774 - 779.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
K. Matsushita, H. Yatsuya, K. Tamakoshi, K. Wada, R. Otsuka, S. Takefuji, K. Sugiura, T. Kondo, T. Murohara, and H. Toyoshima
Comparison of Circulating Adiponectin and Proinflammatory Markers Regarding Their Association With Metabolic Syndrome in Japanese Men
Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 871 - 876.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. Desroches, W. R. Archer, M.-E. Paradis, O. Deriaz, P. Couture, J. Bergeron, N. Bergeron, and B. Lamarche
Baseline Plasma C-Reactive Protein Concentrations Influence Lipid and Lipoprotein Responses to Low-Fat and High Monounsaturated Fatty Acid Diets in Healthy Men
J. Nutr., April 1, 2006; 136(4): 1005 - 1011.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Iwakura, H. Ito, S. Kawano, A. Okamura, T. Kurotobi, M. Date, K. Inoue, and K. Fujii
Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction
Eur. Heart J., March 1, 2006; 27(5): 534 - 539.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
X. Cheng, Y.-H. Liao, J. Zhang, B. Li, H. Ge, J. Yuan, M. Wang, B. Lu, Y. Liu, and Y. Cheng
Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction
Eur J Heart Fail, December 1, 2005; 7(7): 1099 - 1104.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
U. Singh, J. Tabibian, S. K. Venugopal, S. Devaraj, and I. Jialal
Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents
Clin. Chem., December 1, 2005; 51(12): 2252 - 2256.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. S. Ginsburg, M. P. Donahue, and L. K. Newby
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al.
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Circulation, October 25, 2005; 112(17): 2735 - 2752.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. D.M. Engelmann and J. H. Svendsen
Inflammation in the genesis and perpetuation of atrial fibrillation
Eur. Heart J., October 2, 2005; 26(20): 2083 - 2092.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
F. Bruni, A. L. Pasqui, M. Pastorelli, G. Bova, M. Cercignani, A. Palazzuoli, T. Sawamura, A. Auteri, and L. Puccetti
Different Effect of Statins on Platelet Oxidized-LDLReceptor (CD36 and LOX-1) Expressionin Hypercholesterolemic Subjects
Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 417 - 428.
[Abstract] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
M. B. Clearfield
C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease
J Am Osteopath Assoc, September 1, 2005; 105(9): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Inflammation, Atherosclerosis, and Aspects of Insulin Action
Diabetes Care, September 1, 2005; 28(9): 2312 - 2319.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. Tiruvoipati, M. Loubani, M. Lencioni, S. Ghosh, P. W. Jones, and R. L. Patel
Coronary Endarterectomy: Impact on Morbidity and Mortality When Combined With Coronary Artery Bypass Surgery
Ann. Thorac. Surg., June 1, 2005; 79(6): 1999 - 2003.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Ridker, D. A. Morrow, L. M. Rose, N. Rifai, C. P. Cannon, and E. Braunwald
Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l: An Analysis of the PROVE-IT TIMI-22 Trial
J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1644 - 1648.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.P. Empana, D.H. Sykes, G. Luc, I. Juhan-Vague, D. Arveiler, J. Ferrieres, P. Amouyel, A. Bingham, M. Montaye, J.B. Ruidavets, et al.
Contributions of Depressive Mood and Circulating Inflammatory Markers to Coronary Heart Disease in Healthy European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME)
Circulation, May 10, 2005; 111(18): 2299 - 2305.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
The Diabetes Prevention Program Research Group
Intensive Lifestyle Intervention or Metformin on Inflammation and Coagulation in Participants With Impaired Glucose Tolerance
Diabetes, May 1, 2005; 54(5): 1566 - 1572.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. Cohen, D. Singh, P. Greenland, D. M. Lloyd-Jones, A. J. Moss, B. L. Jaber, N. E. Madias, P. M Ridker, C. P. Cannon, and E. Braunwald
C-Reactive Protein Levels and Outcomes after Statin Therapy
N. Engl. J. Med., April 14, 2005; 352(15): 1603 - 1605.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
V. M. Campese, M. K. Nadim, and M. Epstein
Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
I. J. Kullo and C. M. Ballantyne
Conditional Risk Factors for Atherosclerosis
Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230.
[Abstract] [PDF]


Home page
NEJMHome page
P. M Ridker, C. P. Cannon, D. Morrow, N. Rifai, L. M. Rose, C. H. McCabe, M. A. Pfeffer, E. Braunwald, and the Pravastatin or Atorvastatin Evaluation and Inf
C-Reactive Protein Levels and Outcomes after Statin Therapy
N. Engl. J. Med., January 6, 2005; 352(1): 20 - 28.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
M. Ghayour-Mobarhan, D. J. Lamb, N. Vaidya, C. Livingstone, T. Wang, and G. A. A. Ferns
Heat Shock Protein Antibody Titers Are Reduced by Statin Therapy in Dyslipidemic Subjects: A Pilot Study
Angiology, January 1, 2005; 56(1): 61 - 68.
[Abstract] [PDF]


Home page
CirculationHome page
L. M. Biasucci
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper
Circulation, December 21, 2004; 110(25): e560 - e567.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. Marz, H. Scharnagl, M. M. Hoffmann, B. O. Boehm, and B. R. Winkelmann
The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study)
Eur. Heart J., December 1, 2004; 25(23): 2109 - 2119.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Pleiner, G. Schaller, F. Mittermayer, S. Zorn, C. Marsik, S. Polterauer, S. Kapiotis, and M. Wolzt
Simvastatin Prevents Vascular Hyporeactivity During Inflammation
Circulation, November 23, 2004; 110(21): 3349 - 3354.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. O. Obisesan, C. Leeuwenburgh, T. Phillips, R. E. Ferrell, D. A. Phares, S. J. Prior, and J. M. Hagberg
C-Reactive Protein Genotypes Affect Baseline, but not Exercise Training-Induced Changes, in C-Reactive Protein Levels
Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1874 - 1879.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T.-S. Lee, C.-C. Chang, Y. Zhu, and J. Y.-J. Shyy
Simvastatin Induces Heme Oxygenase-1: A Novel Mechanism of Vessel Protection
Circulation, September 7, 2004; 110(10): 1296 - 1302.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Fliser, K. Buchholz, H. Haller, and for the EUropean Trial on Olmesartan and Pravastat
Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation
Circulation, August 31, 2004; 110(9): 1103 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. A. Beckman, J. K. Liao, S. Hurley, L. A. Garrett, D. Chui, D. Mitra, and M. A. Creager
Atorvastatin Restores Endothelial Function in Normocholesterolemic Smokers Independent of Changes in Low-Density Lipoprotein
Circ. Res., July 23, 2004; 95(2): 217 - 223.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C G Perry, S J Cleland, J M Connell, J R Petrie, and N Sattar
Low grade inflammation is notably suppressed by conventional anti-inflammatory treatment: a randomised crossover trial
Heart, July 1, 2004; 90(7): 804 - 805.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C. Kluft
Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C21 - C27.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
D.D. Waters and K.K. Khush
Management of the acute coronary syndrome patient
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C49 - C57.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
I. Jialal, S. Devaraj, and S. K. Venugopal
C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?
Hypertension, July 1, 2004; 44(1): 6 - 11.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Paoletti, A. M. Gotto Jr, and D. P. Hajjar
Inflammation in Atherosclerosis and Implications for Therapy
Circulation, June 15, 2004; 109(23_suppl_1): III-20 - III-26.
[Abstract] [Full Text]


Home page
CirculationHome page
J. Davignon
Beneficial Cardiovascular Pleiotropic Effects of Statins
Circulation, June 15, 2004; 109(23_suppl_1): III-39 - III-43.
[Abstract] [Full Text]


Home page
BloodHome page
R. Kleemann, L. Verschuren, B.-J. de Rooij, J. Lindeman, M. M. de Maat, A. J. Szalai, H. M. G. Princen, and T. Kooistra
Evidence for anti-inflammatory activity of statins and PPAR{alpha} activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro
Blood, June 1, 2004; 103(11): 4188 - 4194.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. P.J. Halcox and J. E. Deanfield
Beyond the Laboratory: Clinical Implications for Statin Pleiotropy
Circulation, June 1, 2004; 109(21_suppl_1): II-42 - II-48.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. L. Brown, K. K. Desai, B. A. Vakili, C. Nouneh, H.-M. Lee, and L. M. Golub
Clinical and Biochemical Results of the Metalloproteinase Inhibition with Subantimicrobial Doses of Doxycycline to Prevent Acute Coronary Syndromes (MIDAS) Pilot Trial
Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 733 - 738.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Kumagai, H. Nakashima, and K. Saku
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model
Cardiovasc Res, April 1, 2004; 62(1): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
F. M. Sacks
High-Intensity Statin Treatment for Coronary Heart Disease
JAMA, March 3, 2004; 291(9): 1132 - 1134.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. Fonseca, C. Desouza, S. Asnani, and I. Jialal
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Endocr. Rev., February 1, 2004; 25(1): 153 - 175.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. M Backes, P. A Howard, and P. M Moriarty
Role of C-Reactive Protein in Cardiovascular Disease
Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Trovati and F. Cavalot
Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20.
[Abstract] [Full Text]


Home page
JAMAHome page
S. M. Grundy
Inflammation, Hypertension, and the Metabolic Syndrome
JAMA, December 10, 2003; 290(22): 3000 - 3002.
[Full Text] [PDF]


Home page
QJMHome page
G.M. Hirschfield and M.B. Pepys
C-reactive protein and cardiovascular disease: new insights from an old molecule
QJM, November 1, 2003; 96(11): 793 - 807.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas
Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review
Ann Intern Med, October 21, 2003; 139(8): 670 - 682.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Ferroni, F. Martini, C. M. Cardarello, P. P. Gazzaniga, G. Davi, and S. Basili
Enhanced Interleukin-1{beta} in Hypercholesterolemia: Effects of Simvastatin and Low-Dose Aspirin
Circulation, October 7, 2003; 108(14): 1673 - 1675.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Haffner and H. Taegtmeyer
Epidemic Obesity and the Metabolic Syndrome
Circulation, September 30, 2003; 108(13): 1541 - 1545.
[Full Text] [PDF]


Home page
CirculationHome page
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, S. J. Leslie, W. J. Sasiela, M. Szarek, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress
High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study
Circulation, September 30, 2003; 108(13): 1560 - 1566.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. M. Blanco-Colio, B. Munoz-Garcia, J. L. Martin-Ventura, C. Lorz, C. Diaz, G. Hernandez, and J. Egido
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Decrease Fas Ligand Expression and Cytotoxicity in Activated Human T Lymphocytes
Circulation, September 23, 2003; 108(12): 1506 - 1513.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Susic, J. Varagic, J. Ahn, M. Slama, and E. D. Frohlich
Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models
J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1091 - 1097.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. B. Rice, L. L. Stoll, W.-G. Li, G. M. Denning, J. Weydert, E. Charipar, W. E. Richenbacher, F. J. Miller Jr, and N. L. Weintraub
Low-Level Endotoxin Induces Potent Inflammatory Activation of Human Blood Vessels: Inhibition by Statins
Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1576 - 1582.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Hognestad, K. Endresen, R. Wergeland, O. Stokke, O. Geiran, T. Holm, S. Simonsen, J. K. Kjekshus, and A. K. Andreassen
Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients
J. Am. Coll. Cardiol., August 6, 2003; 42(3): 477 - 482.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. O. Ventura and M. R. Mehra
C-Reactive protein and cardiac allograft vasculopathy: is inflammation the critical link?
J. Am. Coll. Cardiol., August 6, 2003; 42(3): 483 - 485.
[Full Text] [PDF]


Home page
LupusHome page
C Abud-Mendoza, H de la Fuente, E Cuevas-Orta, L Baranda, J Cruz-Rizo, and R Gonzalez-Amaro
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study
Lupus, August 1, 2003; 12(8): 607 - 611.
[Abstract] [PDF]


Home page
ChestHome page
Y. Almog
Statins, Inflammation, and Sepsis: Hypothesis
Chest, August 1, 2003; 124(2): 740 - 743.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. B. Ledue and N. Rifai
Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment
Clin. Chem., August 1, 2003; 49(8): 1258 - 1271.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. J. A. Jenkins, C. W. C. Kendall, A. Marchie, D. A. Faulkner, J. M. W. Wong, R. de Souza, A. Emam, T. L. Parker, E. Vidgen, K. G. Lapsley, et al.
Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein
JAMA, July 23, 2003; 290(4): 502 - 510.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
M. Schachter
Review: Lipid lowering drugs, inflammation and cardiovascular disease
The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 178 - 182.
[Abstract] [PDF]


Home page
CirculationHome page
A. W. Chan, D. L. Bhatt, D. P. Chew, J. Reginelli, J. P. Schneider, E. J. Topol, and S. G. Ellis
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Circulation, April 8, 2003; 107(13): 1750 - 1756.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
F. Lesperance and N. Frasure-Smith
Depression and coronary artery disease: time to move from observation to trials
Can. Med. Assoc. J., March 4, 2003; 168(5): 570 - 571.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. J. Blake and P. M. Ridker
C-reactive protein and other inflammatory risk markers in acute coronary syndromes
J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 37S - 42S.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. D. Horne, J. B. Muhlestein, J. F. Carlquist, T. L. Bair, T. E. Madsen, N. I. Hart, J. L. Anderson, and for the Intermountain Heart Collaborative (IHC) St
Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease
Circulation, January 21, 2003; 107(2): 258 - 263.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
V. Schachinger and A. M. Zeiher
Atherogenesis--recent insights into basic mechanisms and their clinical impact
Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2055 - 2064.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
N. Stone
Combination therapy: its rationale and the role of ezetimibe
Eur. Heart J. Suppl., December 1, 2002; 4(suppl_J): J19 - J22.
[Abstract] [PDF]


Home page
J. Nutr.Home page
S. Mathur, S. Devaraj, S. M. Grundy, and I. Jialal
Cocoa Products Decrease Low Density Lipoprotein Oxidative Susceptibility but Do Not Affect Biomarkers of Inflammation in Humans
J. Nutr., December 1, 2002; 132(12): 3663 - 3667.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. R. Mehra, P. A. Uber, K. Vivekananthan, S. Solis, R. L. Scott, M. H. Park, R. V. Milani, and C. J. Lavie
Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival
J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1609 - 1614.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. Stefanadis, K. Toutouzas, M. Vavuranakis, E. Tsiamis, D. Tousoulis, D.B. Panagiotakos, S. Vaina, C. Pitsavos, and P. Toutouzas
Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques
Eur. Heart J., November 1, 2002; 23(21): 1664 - 1669.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jialal, I.
Right arrow Articles by Devaraj, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jialal, I.
Right arrow Articles by Devaraj, S.
Related Collections
Right arrow Lipid and lipoprotein metabolism